Search
Rimegepant
go.drugbank.com/drugs/DB12457ApprovedInvestigationalRimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commissio...
Atogepant
go.drugbank.com/drugs/DB16098ApprovedInvestigationalAtogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in Septemb...
CM4620
go.drugbank.com/drugs/DB16466InvestigationalCM4620 (Zegocractin), is under investigation in multiple clinical trials, including NCT04195347 (pancreatitis due to asparaginase), NCT03709342 (PK/PD study in acute pancreatitis), NCT03401190 and NCT04681066 (pancreatitis and SIRS), and...
Vildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigationalVildagliptin (LAF237) is an orally active antihyperglycemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. It is used to manage type II diabetes mellitus, where GLP-1 secretion and insulinotropic effects are i...
Didesmethylrocaglamide
go.drugbank.com/drugs/DB15496ExperimentalDidesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their inse...
Indomethacin
go.drugbank.com/drugs/DB00328ApprovedInvestigationalthrough potent and nonselective inhibition of the enzyme cyclooxygenase (COX), which is the main enzyme responsible for catalyzes the rate-limiting step in prostaglandin and thromboxane biosynthesis via
FK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Tonapofylline
go.drugbank.com/drugs/DB12569InvestigationalTonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.
Efmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalEfmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It ...
Ecallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema. Ecallantide is a recombinant 60-amino-acid protein produced in Pichia pastoris yeast cells ...